Alerta

C-C基序趋化因子受体作为治疗子宫瘢痕新靶点的应用

Resumen de: CN122681898A

本发明公开了C‑C基序趋化因子受体作为治疗子宫瘢痕新靶点的应用。CCR1作为子宫瘢痕疾病的全新治疗靶点，能够推动子宫瘢痕病变持续进展，通过磷酸化下游Six1、促进细胞外基质生成，进而介导子宫瘢痕产生。通过沉默该受体，可有效阻滞子宫瘢痕的发生与发展，提升女性妊娠成功率，并减少各类不良妊娠结局的出现。本方案的制备工艺为：将可电离脂质、DSPC、胆固醇、DMG‑PEG混合溶解在乙醇中，将siCCR1置于柠檬酸缓冲液中，乙醇相和水相通过微流体装置混合，在PBS溶液中透析两小时后制备成脂质纳米粒。该脂质纳米粒与聚卡波非、泊洛沙姆复配，制备得到复合水凝胶。该水凝胶可于子宫病灶局部释放siCCR1，有效抑制组织纤维化、减少胶原沉积，进而实现子宫瘢痕修复。其具备优异的生物相容性，给药方式无创，可实现药物长效缓释，减少给药频次。

一种含有氨基甲酸酯的阳离子脂质、包含其的组合物及用途

Resumen de: CN122685538A

本发明公开了一种含有氨基甲酸酯的阳离子脂质、包含其的组合物及用途，具体公开了一种式(I)所示的阳离子脂质。本发明提供的阳离子脂质能特异性地递送药物到特定的细胞，同时可显著降低细胞毒性，有助于发挥药物的疗效，能够提升药物在体内的靶向递送效率和安全性。

一种透明质酸、L-精氨酸包覆复合纳米粒子及其制备方法

Resumen de: CN122681823A

本发明公开了一种透明质酸、L‑精氨酸包覆复合纳米粒子及其制备方法，涉及医药技术领域；该复合纳米粒子以β‑环糊精包载伏立诺他（SAHA）形成纳米粒子，外层包覆氧化透明质酸（OHA）和L‑精氨酸（L‑Arg）；制备过程中，先通过透析法制得纳米粒子，再依次加入OHA和L‑Arg进行避光反应，最终得到CS@OL复合纳米粒子；该粒子平均粒径为87nm，在室温下21天内保持稳定。本发明复合纳米粒子具有良好的自由基清除能力、细胞相容性、跨内皮递送能力及靶向炎症细胞的能力，能够协同递送SAHA和L‑Arg，调节ROS/NO稳态，抑制炎症反应，适用于动脉粥样硬化等氧化应激相关疾病的治疗。

一种用于特异性检测tRNA来源小片段RNA 5-GlyTCC-L33表达水平的试剂及其模拟物的应用和试剂盒

Resumen de: CN122686807A

本发明涉及生物医药技术领域，具体涉及用于特异性检测tRNA来源小片段RNA 5‑GlyTCC‑L33表达水平的试剂在制备用于胎儿生长受限辅助评估产品中的应用，5‑GlyTCC‑L33模拟物在制备用于胎儿生长受限实验动物模型构建的模型诱导试剂或模型诱导组合物中的应用，以及相关试剂盒；本发明通过对正常妊娠与胎儿生长受限胎盘组织进行小RNA测序分析，发现5‑GlyTCC‑L33在胎儿生长受限胎盘组织中显著上调，通过检测离体胎盘绒毛膜组织样本中5‑GlyTCC‑L33的表达水平，并与正常妊娠对照水平或预设参考阈值比较，可生成体外检测结果或辅助判读信息可作为胎儿生长受限辅助评估的候选分子标志物。

一种纳米材料Q-MNPS及其制备方法和在脑缺血神经保护中的制药新用途

Resumen de: CN122681817A

本发明公开了一种纳米材料Q‑MNPS及其制备方法和在脑缺血神经保护中的制药新用途，涉及生物医药技术领域。包括：金属‑药物配位聚合物内核；包覆所述内核的天然细胞膜外壳；其中，所述金属‑药物配位聚合物内核在活性氧环境下发生解离，释放药物分子；所述天然细胞膜外壳赋予所述纳米颗粒穿透血脑屏障的能力。本发明通过天然细胞膜外壳的生物伪装特性实现血脑屏障穿透，利用金属‑药物配位聚合物内核的活性氧响应性在缺血病灶定点释放药物，具有优异的神经保护作用，能够显著改善神经功能缺损并降低死亡率。

负载二烯丙基三硫化物的长双歧杆菌来源细胞外囊泡纳米复合物及其制备方法、应用

Resumen de: CN122681819A

本发明公开一种负载二烯丙基三硫化物的长双歧杆菌来源细胞外囊泡纳米复合物，包括：长双歧杆菌来源细胞外囊泡（BL‑EVs），以及负载于BL‑EVs中的二烯丙基三硫化物（DATS）；纳米复合物是通过将BL‑EVs与DATS混合后进行共挤出及孵育处理制得的、具有单分散囊泡结构的纳米复合物实体。本发明的纳米复合物具备细胞内微环境刺激响应性，在被牙周相关细胞摄取进入胞内后，特异性响应于胞内谷胱甘肽微环境触发内部有机硫键断裂，并在胞内靶向缓释硫化氢，用以通过上调靶细胞抗氧化保护蛋白的表达与活性以产生抗氧化增效作用，并在此基础上，协同诱导巨噬细胞向抗炎修复型M2巨噬细胞重塑，同时上调牙龈成纤维细胞抗铁死亡保护蛋白的表达与活性以阻断其铁死亡进程。

一种用于椎间盘退变修复的聚多巴胺修饰ZnO/BaTiO3异质结复合材料及其制备方法

Resumen de: CN122682090A

本发明公开了一种用于椎间盘退变修复的聚多巴胺修饰ZnO/BaTiO3异质结复合材料及其制备方法，属于生物医用材料技术领域。该材料以四方相钛酸钡为核心、表面原位生长氧化锌构建II型异质结，并包覆聚多巴胺功能层。制备时，先水热法制备钛酸钡，再经溶剂蒸发与高温煅烧引入氧化锌，最后在多巴胺溶液中自聚包覆。本发明利用超声驱动异质结产生声电耦合效应，II型异质结促进载流子分离以提升压电催化活性，PDA涂层清除活性氧、缓解炎症。体外实验证实该材料促进髓核细胞基质合成、抑制炎症，动物实验验证其延缓椎间盘退变。本发明通过“声电转化‑电荷分离‑电刺激‑环境重塑”一体化设计，为深部组织修复提供了高效无创策略。

一种核酸药物选择性递送的膦酯化可电离脂质及其制备方法与应用

Resumen de: CN122685654A

本发明属于生物医药的技术领域，公开了一种核酸药物选择性递送的膦酯化可电离脂质及其制备方法与应用。所述膦酯化可电离脂质其结构通式为式I，式I中Cn为含有膦酯的结构，Nn为含氮的环状结构或含氮的胺基基团，B为O或NH；Ln作为连接键。本发明还公开了膦酯化可电离脂质的制备方法。本发明的膦酯化可电离脂质用于制备膦酯化可电离脂质纳米颗粒，作为核酸药物选择性递送至心、肺脏、脾脏、肝脏和/或肌肉递送载体。本发明的可电离脂质协同整合了膜稳定性与内涵体逃逸功能，有效规避传统靶向修饰中存在的蛋白冠屏蔽效应，能够将核酸药物高效、安全地递送至肝外器官，特别是肺和脾。式I：。

STEALTH-STABILIZED LIPO-POLYAMINO ACIDS

Resumen de: US20260256704A1

0000 It relates to lipo-polyamino acid conjugates of formula (I), and acceptable salts, stereoisomers and mixtures thereof. It also relates to self-assembled particles comprising these lipo-polyamino acid conjugates and optionally active agents, and to compositions comprising the lipo-polyamino acid conjugates or the self-assembled particles comprising them. It relates as well to the use of the lipo-polyamino acid conjugates, self-assembled particles, or compositions comprising them in medicine, cosmetics and diagnostics, and to the use of the lipo-polyamino acid conjugates of formula (I) as carriers. 0000

REHYDRATABLE, MORPHOLOGICALLY DIVERSE NANOCARRIER POWDERS

Resumen de: US20260256698A1

Provided herein are rehydratable powdered formulations of nanocarriers that can be used to encompass hydrophobic or hydrophilic cargo. The formulations can be used for medicinal, agricultural, and research applications. Methods of making the formulations are also provided.

LIPID NANOPARTICLES TARGETING LIVER SINUSOIDAL ENDOTHELIAL CELLS AND USE THEREOF

Resumen de: WO2026179939A1

Lipid nanoparticles (LNPs) targeting liver sinusoidal endothelial cells and the use thereof. The LNPs consist of a cationic ionized lipid, an auxiliary lipid, a ligand-modified PEGylated lipid, and cholesterol. The auxiliary lipid and the ligand-modified PEGylated lipid target surface receptors of the liver sinusoidal endothelial cells (LSECs). The LNPs enhance, by means of a multivalent targeting design, specific uptake by LSECs, and encapsulate an RNA drug for treating an allergic disease or an autoimmune disease. The RNA drug can encode at least one epitope of an antigen causing an allergic or autoimmune disease. The LNPs can efficiently target LSECs to induce immune tolerance, providing a new antigen-specific immunomodulatory strategy for the treatment of allergic diseases or autoimmune diseases.

IONIZABLE LIPID MOLECULE COMPRISING TOCOPHEROL STRUCTURE, LIPID NANOPARTICLE COMPRISING SAME, AND USE THEREOF

Resumen de: WO2026178739A1

The present invention relates to an ionizable lipid molecule comprising a tocopherol structure, a lipid nanoparticle comprising same, and use thereof. Specifically, provided are an ionizable lipid molecule comprising a structure of a tocopherol and a derivative thereof as represented by formula (1), a lipid nanoparticle comprising same, a preparation method therefor, and use thereof. Compared with ionizable lipid molecules conventionally used in the art, the lipid nanoparticle prepared from the ionizable lipid molecule represented by formula (1) of the present invention can significantly improve nucleic acid delivery efficiency and expression.

ORAL NANOPARTICLES FOR BIOACTIVE COMPOUND, AND METHOD OF PREPARING SAME

Resumen de: US20260256708A1

Provided are: oral nanoparticles for enabling oral administration of a bioactive compound which is typically administered by injection due to having low bioavailability attributable to issues with solubility, disintegration in the digestive tract, and intestinal permeability; a method of formulating the oral nanoparticles; and a use of the oral nanoparticles. In addition, provided are: oral nanoparticles capable of maintaining or protecting the balance in the gut microbiome by minimizing the exposure of the gut microbiome to a bioactive compound; a formulation; and a use of same.

ORAL GENE DELIVERY CARRIER

Resumen de: WO2026182546A1

The present invention relates to an oral gene delivery carrier and a gene delivery composition comprising same. The present invention comprises lipid nanoparticles surface-modified with a bile acid-based polymer (GCGA), and provides improved stability in the gastrointestinal (GI) environment, enhanced mucosal adhesion and cellular uptake, and significantly increased gene delivery efficiency in intestinal epithelial cells, thereby being useful for the development of an oral gene therapeutic agent.

pH-RESPONSIVE LIPID DERIVATIVE

Resumen de: WO2026181880A1

The present invention provides a pH-responsive lipid derivative represented by formula (1): R1-L1-R2 (in the formula, R1 represents a lipid moiety, L1 represents NH or O, and R2 represents a polymer moiety having a repeating unit represented by formula (2) and a repeating unit represented by formula (3)), wherein the amount of a repeating unit (B) based on the total amount of a repeating unit (A) and the repeating unit (B) is 6 to 50 mol% (the symbols in formulae (2) and (3) are as defined in the description).

PIEZOELECTRIC CHITOSAN NANOPARTICLES AND THEIR USE IN BIOMEDICAL APPLICATIONS

Resumen de: WO2026181030A1

It forms an object of the present invention chitosan piezoelectric nanoparticles (ChNPs), methods to prepare them and their use.

PEGYLATED LIPID NANOPARTICLES MODIFIED WITH CELL PENETRATING PEPTIDES FOR DELIVERY OF NUCLEIC ACIDS

Resumen de: WO2026183439A1

The present disclosure provides compositions of lipid nanoparticles including lipid components and a cell-penetrating peptide conjugated to the lipid components useful for the delivery of nucleic acids including mRNAs, and methods thereof. These compositions may be used to treat a disease or disorder for which the delivery of a nucleic acid is therapeutically effective.

NANOCOMPOSITE COMPOSITION

Resumen de: WO2026180833A1

The subject of the invention is a core–shell structured nanocomposite composition comprising a core containing glibenclamide and soybean lecithin having phosphatidylcholine as a main component, and a shell containing a Poloxamer polymer. The invention further relates to the use of the nanocomposite composition in human medicine and/or veterinary medicine.

TARGETED LIPID NANOPARTICLES

Resumen de: WO2026183200A1

The present disclosure provides, among other things, targeted lipid nanoparticles and methods of targeted making lipid nanoparticles.

MULTI-SPECIFIC TARGETING COMPOSITIONS

Resumen de: WO2026183563A2

Compositions and methods for targeted delivery of a lipid nanoparticle (LNP) are described herein. In some embodiments, the compositions comprise (a) a hepatoavoidant lipid nanoparticle (LNP) associated with an RNA polynucleotide that comprises an expression sequence, and (b) a multi-specific targeting moiety, wherein the multi-specific targeting moiety binds (i) at least one target in or on the hepatoavoidant LNP and (ii) at least one cell-specific target in or on a cell. In some embodiments, the compositions comprise a multi-specific targeting moiety or an RNA polynucleotide comprising an expression sequence encoding a multi-specific targeting moiety, where the multi-specific targeting moiety binds (a) at least one target in or on an LNP, and (b) at least one cell-specific target. When expressed, the multi-specific targeting moiety allows for delivery of the LNP to the cells expressing the cell-specific target, by bringing the LNP in close proximity to the cells. In some embodiments, the LNP comprises an expression sequence encoding a therapeutic molecule, and the methods allow for targeted delivery for treating or preventing a disease or disorder.

ACTIVATION OF CELLS WITH SELF-ASSEMBLED SPHERES

Resumen de: WO2026180422A1

The invention is directed to a compound for cell activation having a mean diameter between 500 nm and 10 µm and provided with one or more antigen recognizing moieties capable of activating cells characterized in comprising - first particles with a mean diameter of less than 500 nm which are provided on the surface with one or more first oligonucleotides having a length of 5 to 50 nucleotides - second particles with a mean diameter of less than 500 nm which are provided on the surface with one or more second oligonucleotides having a length of 5 to 50 nucleotides and with one or more antigen recognizing moieties wherein the first and second oligonucleotides have complementary sequences capable of hybridizing to each other, thereby binding the first and second particles to each other.

BRANCHED CATIONIC LIPID CONTAINING ESTER BOND AND USE THEREOF

Resumen de: WO2026179355A1

The present application provides a branched cationic lipid containing an ester bond, the structure of which is represented by formula (1), wherein the definition of each symbol is consistent with that described herein. The branched cationic lipid containing an ester bond has a plurality of hydrophobic hydrocarbon tail chains. The cross-sectional area of the hydrophobic end increases, forming a conical geometric configuration, which is conducive to promoting membrane fusion and content release; moreover, a charged head group can interact with oppositely charged molecules on the cell membrane, thereby enabling the multi-tailed lipid to pass through the cell membrane more easily and exert its endosome-disrupting effect inside the cell, and thus improving drug release efficiency. The branched cationic lipid containing an ester bond of the present application comprises one or more biodegradable groups between a branching center and the hydrophobic tails. The presence of the degradable groups enables a lipid nanoparticle (LNP) prepared from the branched cationic lipid to be degraded timely within endosomes, such that the endosomal escape of drug molecules (such as nucleic acids) is promoted, thereby solving the problem that drugs delivered into the cell fail to exert their effects.

PH-RESPONSIVE SYNTHETIC PEPTIDE SHUTTLE AGENTS

Resumen de: WO2026178657A1

Described herein are pH-responsive synthetic peptide shuttle agent having increased cargo transduction activity at acidic pH than at neutral pH. The pH-responsive synthetic peptide shuttle agent generally comprises an amphipathic alpha-helical motif when in acidic pH, the amphipathic alpha-helical motif having solvent-exposed surface comprising a discrete hydrophilic cationic face and a discrete hydrophobic face. The pH-responsive synthetic peptide shuttle agent described herein may be further conjugated to a cargo for intracellular delivery, and/or a targeting ligand for tissue-specific delivery. Also described herein are lipid nanoparticles (LNPs) incorporating synthetic peptide shuttle agents or pH- responsive synthetic peptide shuttle agents for improved payload delivery to the cytosol.

NANOPARTICLE POLYMER ENCAPSULATION SYSTEM

Resumen de: US20260256943A1

Generally, a nanomaterial polymer encapsulation system useful in the production of nanocomposites comprising an inorganic nanoparticle encapsulated in a hydrophobic region of a polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanocomposite conjugates.Specifically, particular embodiments can comprise nanocomposites including one or more inorganic nanoparticles including, metal and non-metal isotopes, a superparamagnetic iron oxide nanoparticle (“SPION”), and/or quantum dots encapsulated in a polystyrene-b-polyethylene glycol affording a functional group that can be activated to conjugate antibodies, modified antibodies, or antibody fragments for the capture of target moieties which in suspension can be nebulized into an inductively coupled plasma time-of-flight mass spectrometry instrument to identify and quantify diverse features of cellular systems.

LIPID NANOPARTICLE

Nº publicación: US20260256706A1 03/09/2026

Solicitante:

NATIONAL UNIV CORPORATION HOKKAIDO UNIV [JP]
NITTO DENKO CORP [JP]
National University Corporation Hokkaido University
Nitto Denko Corporation

Resumen de: US20260256706A1

The present invention addresses the problem of providing lipid nanoparticles which function as gene transfer carriers capable of selective transfer to the liver or spleen. Lipid nanoparticles which contain a pH-sensitive cationic lipid represented by formula (I) a represents an integer of 3-5; b represents 0 or 1; R1 and R2 each independently represent a group represented by general formula (A) (R11 and R12 each independently represent a linear or branched C2-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); and X represents a group represented by general formula (B)(d represents an integer of 0-3; and R3 and R4 each independently represent a C1-4 alkyl group or C2-4 alkenyl group, while R3 and R4 may form a 5- to 7-membered non-aromatic heterocycle) or represents a 5- to 7-membered non-aromatic heterocyclic group. (I) (R1)(R2)C(OH)—(CH2)a-(O—CO)b-X. (A): (R11)(R12)—CH—(CO—O)c-(CH2)v-. (B):—(CH2)d-N(R3)(R4).